The Rock Springs Capital Management LP Maintains Position in Genocea Biosciences Inc. (GNCA)

The Rock Springs Capital Management LP Maintains Position in Genocea Biosciences Inc. (GNCA)

Rock Springs Capital Management LP maintained its position in Genocea Biosciences Inc. (NASDAQ:GNCA) during the third quarter, Holdings Channel reports. The institutional investor owned 480,000 shares of the company’s stock at the end of the third quarter. Rock Springs Capital Management LP’s holdings in Genocea Biosciences were worth $2,458,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Alpine Partners VI LLC purchased a new position in Genocea Biosciences during the second quarter valued at approximately $120,000. TFS Capital LLC purchased a new position in Genocea Biosciences during the second quarter valued at approximately $133,000. Northern Trust Corp raised its position in Genocea Biosciences by 24.3% in the third quarter. Northern Trust Corp now owns 34,636 shares of the company’s stock valued at $177,000 after buying an additional 6,763 shares during the period. Dimensional Fund Advisors LP purchased a new position in Genocea Biosciences during the second quarter valued at approximately $143,000. Finally, Ameriprise Financial Inc. purchased a new position in Genocea Biosciences during the second quarter valued at approximately $156,000. 54.61% of the stock is currently owned by institutional investors.

Genocea Biosciences Inc. (NASDAQ:GNCA) traded down 1.85% during mid-day trading on Thursday, hitting $4.24. The company had a trading volume of 84,018 shares. The stock’s 50 day moving average price is $4.32 and its 200 day moving average price is $4.50. The firm’s market cap is $120.33 million. Genocea Biosciences Inc. has a 52-week low of $2.56 and a 52-week high of $8.07.

Genocea Biosciences (NASDAQ:GNCA) last issued its quarterly earnings results on Thursday, November 3rd. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by $0.01. On average, equities research analysts predict that Genocea Biosciences Inc. will post ($1.64) EPS for the current fiscal year.

Several research analysts have commented on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $15.00 price target on shares of Genocea Biosciences in a research report on Friday, December 16th. Zacks Investment Research raised Genocea Biosciences from a “sell” rating to a “hold” rating in a report on Tuesday, November 8th. FBR & Co reissued an “outperform” rating and issued a $17.00 target price on shares of Genocea Biosciences in a report on Monday, November 14th. Vetr lowered Genocea Biosciences from a “strong-buy” rating to a “buy” rating and set a $5.12 target price on the stock. in a report on Monday, December 19th. Finally, Cowen and Company set a $40.00 target price on Genocea Biosciences and gave the company a “buy” rating in a report on Wednesday, December 14th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Genocea Biosciences has an average rating of “Buy” and a consensus price target of $15.27.

About Genocea Biosciences

Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.

Want to see what other hedge funds are holding GNCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genocea Biosciences Inc. (NASDAQ:GNCA).

Related posts

Leave a Comment